Ampio Pharmaceuticals Price Performance
Ampio Pharmaceuticals stock opened at $2.35 on Friday. Ampio Pharmaceuticals has a fifty-two week low of $2.35 and a fifty-two week high of $13.20. The stock has a fifty day moving average of $3.20 and a two-hundred day moving average of $4.25.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on Ampio Pharmaceuticals in a research report on Sunday, November 12th. They set a “sell” rating for the company.
Institutional Investors Weigh In On Ampio Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. HRT Financial LP boosted its holdings in Ampio Pharmaceuticals by 1,399.2% in the first quarter. HRT Financial LP now owns 217,052 shares of the company’s stock valued at $50,000 after acquiring an additional 202,574 shares during the last quarter. Bank of Montreal Can acquired a new position in Ampio Pharmaceuticals in the first quarter valued at $168,000. Price T Rowe Associates Inc. MD boosted its holdings in Ampio Pharmaceuticals by 73.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock valued at $66,000 after acquiring an additional 166,979 shares during the last quarter. Virtu Financial LLC acquired a new position in Ampio Pharmaceuticals in the second quarter valued at $72,000. Finally, Two Sigma Advisers LP boosted its holdings in Ampio Pharmaceuticals by 304.3% in the third quarter. Two Sigma Advisers LP now owns 432,216 shares of the company’s stock valued at $26,000 after acquiring an additional 325,300 shares during the last quarter. Hedge funds and other institutional investors own 3.10% of the company’s stock.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.
- Five stocks we like better than Ampio Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Williams-Sonoma is a steal for buy-and-hold investors
- Video Game Stocks: How to Invest in Gaming
- A closer look at Warren Buffett’s latest surprise purchase
- Most Volatile Stocks, What Investors Need to Know
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.